LAUSR

In “Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee,” Price et al. provide evidence-based practice recommendations on the treatment of painful diabetic neuropathy (PDN). Argoff noted that because many patients with PDN discontinue these treatments because of lack of benefit or intolerance within 6 months, future guidelines on management of PDN should include other therapies, such as spinal cord stimulation (SCS), which may benefit patients with refractory PDN. In their experience, up to 85 percent of refractory patients with PDN responded to SCS. Callaghan, the senior author on this guideline, agreed there is a need for new therapies for PDN, but noted the only data on SCS for PDN is from unblinded research. Additional studies on interventions for PDN are needed.